Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin s...
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
- Associated Therapies
- -
Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 524
- Registration Number
- NCT04697186
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 658
- Registration Number
- NCT04678492
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 270
- Registration Number
- NCT04667299
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Effectiveness of Rifabutin for Treatment of Helicobacter Pylori
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT04652284
Quadruple vs Tailored Therapy in the Treatment of Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- University of Split, School of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT04621487
- Locations
- 🇭🇷
University hospital Split, Split, Croatia
Comparison of Three Antibiotic Protocols in Prevention of Infection in Dental Implant Surgery
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 450
- Registration Number
- NCT04620018
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2022-01-13
- Target Recruit Count
- 339
- Registration Number
- NCT04558502
The Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 30
- Registration Number
- NCT04552080
- Locations
- 🇦🇹
Medical University of Graz, University Hospital for Dentistry and Oral Health, Graz, Austria
Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth
- Conditions
- Interventions
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04444011
Alternative Antibiotic Regimen in Periodontitis Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Istanbul Medipol University Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT04353362
- Locations
- 🇹🇷
Begum Alkan, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.